United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 3 minute read Pharma Industry News Biogen to acquire Nightstar Therapeutics in a deal worth $800m to target retinal diseases In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to… bypharmanewsdailyMarch 31, 2019